Poniard Pharmaceuticals, Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer

Oct 17, 2007 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that its lead product candidate, picoplatin, has been granted orphan medicinal product* designation for the treatment of small cell lung cancer (SCLC) by the European Commission. This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA)... Poniard Pharmaceuticals' Press Release-